可逆性卡博替尼诱导性心肌病。
Reversible Cabozantinib-Induced Cardiomyopathy.
机构信息
The Division of Cardiology, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada.
出版信息
Can J Cardiol. 2019 Apr;35(4):544.e1-544.e2. doi: 10.1016/j.cjca.2018.12.025. Epub 2018 Dec 29.
Cabozantinib is a multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factor receptor, as well as MET, RET, and AXL. It is currently approved for treating advanced thyroid and kidney cancers, and is being investigated in other cancers. We present a case of reversible heart failure due to cabozantinib use in a 70-year-old man with metastatic renal cell carcinoma. This is, to our knowledge, one of the first reported cases of cardiomyopathy associated with cabozantinib use.
卡博替尼是一种多靶点酪氨酸激酶抑制剂，对血管内皮生长因子受体以及 MET、RET 和 AXL 均有活性。目前该药已获批用于治疗晚期甲状腺癌和肾癌，并且正在其他癌症中进行研究。我们报告了一例 70 岁男性转移性肾细胞癌患者因使用卡博替尼而导致的可逆性心力衰竭。据我们所知，这是首例报道的与卡博替尼使用相关的心肌病病例之一。
Zotero 插件